MapLight Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:MPLT Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Role	Shares	Max Price
28 Oct 25	BuyUS$92,499,992	Catalyst4, Inc	Company		5,441,176	US$17.00
28 Oct 25	BuyUS$16,199,997	Jim Trenkle	Individual		952,941	US$17.00

Insider Trading Volume

Insider Buying: MPLT insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of MPLT?
Owner Type	Number of Shares	Ownership Percentage
Institutions	1,426,400	3.27%
Individual Insiders	4,613,931	10.6%
General Public	17,903,627	41%
Private Companies	19,697,464	45.1%

Dilution of Shares: MPLT only recently listed within the past 12 months

Top Shareholders

Top 11 shareholders own 58.98% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
45.1%	Catalyst4, Inc	19,697,464	US$333.1m	0%	no data
8.45%	Jim Trenkle	3,686,622	US$62.3m	0%	no data
3.27%	Forbion Capital Partners B.V.	1,426,400	US$24.1m	0%	3.15%
1.11%	Christopher Kroeger	484,565	US$8.2m	0%	no data
0.3%	James Lillie	129,095	US$2.2m	0%	no data
0.22%	Anatol Kreitzer	94,007	US$1.6m	0%	no data
0.19%	Jonathan Gillis	80,863	US$1.4m	0%	no data
0.13%	Vishwas Setia	56,578	US$956.7k	0%	no data
0.1%	Kristopher Hanson	44,602	US$754.2k	0%	no data
0.073%	Robert Malenka	31,672	US$535.5k	0%	no data
0.014%	Maria Walker	5,927	US$100.2k	0%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/11/04 05:00
End of Day Share Price	2025/11/04 00:00
Earnings	2025/06/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

MapLight Therapeutics, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.